journal article·2015-12-23

Multi-targeting Peptide-Functionalized Nanoparticles Recognized Vasculogenic Mimicry, Tumor Neovasculature, and Glioma Cells for Enhanced Anti-glioma Therapy

Xingye Feng, Jianhui Yao, Xiaoling Gao, Yixian Jing, Ting Kang, Di Jiang, Tianze Jiang, Jingxian Feng, Qianqian Zhu, Xinguo Jiang, Jun Chen

Publisher page

Abstract

Chemotherapy failure of glioma, the most aggressive and devastating cancer, might be ascribed to the physiologic barriers of the tumor mainly including heterogeneous tumor perfusion and vascular permeability, which result in a limited penetration of chemotherapeutics. Besides, the vasculogenic mimicry (VM) channels, which are highly resistant to anti-angiogenic therapy and serve as a complement of angiogenesis, were abound in glioma and always associated with tumor recurrence. In order to enhance the therapy effect of anti-glioma, we developed a PEG-PLA-based nanodrug delivery system (nanoparticles, NP) in this study and modified its surface with CK peptide, which was composed of a human sonic hedgehog (SHH) targeting peptide (CVNHPAFAC) and a KDR targeting peptide (K237) through a GYG linker, for facilitating efficient VM channels, tumor neovasculature, and glioma cells multi-targeting delivery of paclitaxel. In vitro cellular assay showed that CK-NP-PTX not only exhibited the strongest antiproliferation effect on U87MG cells and HUVEC cells but also resulted in the most efficient destruction of VM channels when compared with CVNHPAFAC-NP, K237-NP, and the unmodified ones. Besides, CK-NP accumulated more selectively at the glioma site as demonstrated by in vivo and ex vivo imaging. As expected, the glioma-bearing mice treated with CK-NP-PTX achieved the longest median survival time compared to those treated with CVNHPAFAC-NP-PTX and K237-NP-PTX. These findings indicated that the multi-targeting therapy mediated by CK peptide might provide a promising way for glioblastoma therapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, People’s Republic of China

Department of Pharmacology, Institute of Medical Sciences, Shanghai Jiaotong University School of Medicine, 280 South Chongqing Road, Shanghai 200025, People’s Republic of China

Funding

Program for New Century Excellent Talents in University · Ministry of Science and Technology of the People's Republic of China · National Natural Science Foundation of China · Shanghai Science and Technology Committee

References (57)

Show source-provided references
1. 10.1016/j.biomaterials.2014.11.05410.1016/j.biomaterials.2014.11.054 ↗
2. 10.1016/j.biomaterials.2007.06.01110.1016/j.biomaterials.2007.06.011 ↗
3. 10.1155/2013/35103110.1155/2013/351031 ↗
4. 10.1016/0026-2862(77)90141-810.1016/0026-2862(77)90141-8 ↗
5. 10.1155/2012/48304010.1155/2012/483040 ↗
6. 10.1158/0008-5472.CAN-10-048910.1158/0008-5472.CAN-10-0489 ↗
7. 10.1073/pnas.07258639910.1073/pnas.072586399 ↗
8. 10.1016/j.ccr.2012.05.03710.1016/j.ccr.2012.05.037 ↗
9. 10.1158/1535-7163.MCT-13-106710.1158/1535-7163.MCT-13-1067 ↗
10. 10.1074/jbc.M111.33454010.1074/jbc.M111.334540 ↗
11. 10.1007/s12032-012-0245-510.1007/s12032-012-0245-5 ↗
12. 10.1016/S0002-9440(10)64739-610.1016/S0002-9440(10)64739-6 ↗
13. 10.1007/s12032-010-9765-z10.1007/s12032-010-9765-z ↗
14. 10.5732/cjc.012.1029210.5732/cjc.012.10292 ↗
15. 10.1016/j.prp.2011.07.01210.1016/j.prp.2011.07.012 ↗
16. 10.1158/1078-0432.CCR-11-323710.1158/1078-0432.CCR-11-3237 ↗
17. 10.1074/jbc.M20310320010.1074/jbc.M203103200 ↗
18. 10.1016/j.biomaterials.2009.11.04710.1016/j.biomaterials.2009.11.047 ↗
19. 10.1016/j.biomaterials.2013.04.06210.1016/j.biomaterials.2013.04.062 ↗
20. 10.1371/annotation/aed5b555-b826-4591-8aa6-284ad888627d10.1371/annotation/aed5b555-b826-4591-8aa6-284ad888627d ↗
21. 10.1158/1541-7786.MCR-10-050110.1158/1541-7786.MCR-10-0501 ↗
22. 10.1371/journal.pone.006913210.1371/journal.pone.0069132 ↗
23. 10.1007/s11060-009-0082-310.1007/s11060-009-0082-3 ↗
24. 10.1038/nrc122910.1038/nrc1229 ↗
25. 10.1007/s10456-007-9078-910.1007/s10456-007-9078-9 ↗
26. 10.1179/016164110X1268129083136010.1179/016164110X12681290831360 ↗
27. 10.1016/S0002-9440(10)65173-510.1016/S0002-9440(10)65173-5 ↗
28. 10.1007/s11596-012-0060-410.1007/s11596-012-0060-4 ↗
29. Yang Z. · Int. J. Clin. Exp. Med. · 2015 · 8 · 9931
30. 10.3892/ijo.25.6.160910.3892/ijo.25.6.1609 ↗
31. 10.2147/DDDT.S7947510.2147/DDDT.S79475 ↗
32. 10.1021/acsami.5b0459610.1021/acsami.5b04596 ↗
33. 10.1016/j.biomaterials.2014.06.02210.1016/j.biomaterials.2014.06.022 ↗
34. 10.1016/j.jconrel.2013.09.01310.1016/j.jconrel.2013.09.013 ↗
35. 10.1021/mp800049w10.1021/mp800049w ↗
36. 10.1021/mp800051m10.1021/mp800051m ↗
37. 10.1038/nnano.2007.7010.1038/nnano.2007.70 ↗
38. 10.1016/j.biomaterials.2011.07.00410.1016/j.biomaterials.2011.07.004 ↗
39. 10.1111/j.1445-2197.2010.05585.x10.1111/j.1445-2197.2010.05585.x ↗
40. 10.1177/109980040325686010.1177/1099800403256860 ↗
41. 10.1016/j.biomaterials.2011.02.04410.1016/j.biomaterials.2011.02.044 ↗
42. 10.1016/j.biomaterials.2013.09.00110.1016/j.biomaterials.2013.09.001 ↗
43. 10.1615/CritRevTherDrugCarrierSyst.v18.i6.3010.1615/CritRevTherDrugCarrierSyst.v18.i6.30 ↗
44. 10.1038/nrc189310.1038/nrc1893 ↗
45. 10.1016/j.biomaterials.2012.11.01610.1016/j.biomaterials.2012.11.016 ↗
46. 10.1016/j.biomaterials.2013.08.03910.1016/j.biomaterials.2013.08.039 ↗
47. 10.1021/acs.bioconjchem.5b0037910.1021/acs.bioconjchem.5b00379 ↗
48. 10.1158/0008-5472.CAN-06-211710.1158/0008-5472.CAN-06-2117 ↗
49. 10.1016/j.actbio.2013.11.00310.1016/j.actbio.2013.11.003 ↗
50. 10.1016/j.biomaterials.2013.04.02510.1016/j.biomaterials.2013.04.025 ↗
51. 10.1016/j.biomaterials.2013.03.03610.1016/j.biomaterials.2013.03.036 ↗
52. 10.1016/j.biomaterials.2014.01.08210.1016/j.biomaterials.2014.01.082 ↗
53. 10.1016/j.biomaterials.2012.09.04410.1016/j.biomaterials.2012.09.044 ↗
54. 10.1021/acs.molpharmaceut.5b0022210.1021/acs.molpharmaceut.5b00222 ↗
55. 10.1016/j.biomaterials.2011.08.05510.1016/j.biomaterials.2011.08.055 ↗
56. 10.1016/j.biomaterials.2014.03.04910.1016/j.biomaterials.2014.03.049 ↗
57. 10.1016/j.biomaterials.2014.05.04010.1016/j.biomaterials.2014.05.040 ↗